Poseida Therapeutics Stock – is a Buy, Sell or Hold?

The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. Poseida Therapeutics P/E ratio is -1.08. it has increased by a third in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into Poseida Therapeutics’s P/E ratio

What is Poseida Therapeutics P/E Ratio?

The P/E ratio of Poseida Therapeutics is -1.08, which represents a 68.33 % increase over the same period last year. their average P/E ratio is 166.82 and their 5-year average is 90.52.

What is Poseida Therapeutics Net EPS?

Poseida Therapeutics’ net earnings for the last quarter were -2.34 US dollars, which represents a 8.95% increase over the same period last year.

Who are Poseida Therapeutics Competitors?

Based on Jika.io AI model, Capricor Therapeutics, Eiger BioPharmaceuticals, Gamida Cell, GeNeuro SA, Longeveron, La Jolla Pharmaceutical, Reneo Pharmaceuticals, Synlogic are considered to be Poseida Therapeutics’s competitors because the companies operate within the same industry as Poseida Therapeutics and are targeting the same customer base. in addition, competitors typically share a similar market capitalization as Poseida Therapeutics.

Who is Poseida Therapeutics’s Biggest competitor?

Poseida Therapeutics’ biggest competitor is Capricor Therapeutics, based on the Jika.io AI model. it has a similar market capitalization to Poseida Therapeutics within the industry, it dominates a similar share of the market as Poseida Therapeutics, and it provides and markets very similar services.

What industry is Poseida Therapeutics in?

Poseida Therapeutics is part of the biotechnology and healthcare industry.

Poseida Therapeutics vs Capricor Therapeutics

Market Cap: Poseida Therapeutics’s Market Cap of 158642896 is higher than Capricor Therapeutics Market Cap of 87810360.
Average Volume: Poseida Therapeutics’s Average Volume of 245156.0 is higher than Capricor Therapeutics Average Volume of 112428.0.
Beta: Poseida Therapeutics’s Beta of 0.0 is lower than Capricor Therapeutics Beta of 5.39.
Revenue: Poseida Therapeutics’s Revenue of 31238.0 is higher than Capricor Therapeutics Revenue of 244.9.
Net Income: Poseida Therapeutics’s Net Income of -124974.0 is lower than Capricor Therapeutics Net Income of -20022.52.
Gross Profit: Poseida Therapeutics’s Gross Profit of 0.0 is lower than Capricor Therapeutics Gross Profit of 0.0.
Ebitda: Poseida Therapeutics’s Ebitda of -128332.0 is lower than Capricor Therapeutics Ebitda of -20022.52.
P/E Ratio: Poseida Therapeutics’s P/E Ratio of -1.08 is lower than Capricor Therapeutics P/E Ratio of -32.63.
P/S Ratio: Poseida Therapeutics’s P/S Ratio of 110.29 is higher than Capricor Therapeutics P/S Ratio of -2160.67.
P/B Ratio: Poseida Therapeutics’s P/B Ratio of 1.53 is lower than Capricor Therapeutics P/B Ratio of 3.56.
P/FCF Ratio: Poseida Therapeutics’s P/FCF Ratio of -1.26 is lower than Capricor Therapeutics P/FCF Ratio of 5.93.
ROE: Poseida Therapeutics’s ROE of -0.98 is higher than Capricor Therapeutics ROE of -0.09.
ROA: Poseida Therapeutics’s ROA of -0.59 is higher than Capricor Therapeutics ROA of -0.04.
Return On Capital Employed: Poseida Therapeutics’s Return On Capital Employed of -0.79 is higher than Capricor Therapeutics Return On Capital Employed of -0.47.
Gross Profit Margin: Poseida Therapeutics’s Gross Profit Margin of 0.0 is lower than Capricor Therapeutics Gross Profit Margin of 0.0.
Assets (Total): Poseida Therapeutics’s Assets (Total) of 269.309M is lower than Capricor Therapeutics Assets (Total) of 41.33M.
Debt (Total): Poseida Therapeutics’s Debt (Total) of 61.198M is higher than Capricor Therapeutics Debt (Total) of 0.0.

Poseida Therapeutics vs Eiger BioPharmaceuticals

Market Cap: Poseida Therapeutics’s Market Cap of 158642896 is lower than Eiger BioPharmaceuticals Market Cap of 295165952.
Average Volume: Poseida Therapeutics’s Average Volume of 245156.0 is lower than Eiger BioPharmaceuticals Average Volume of 483856.0.
Beta: Poseida Therapeutics’s Beta of 0.0 is lower than Eiger BioPharmaceuticals Beta of 1.57.
Revenue: Poseida Therapeutics’s Revenue of 31238.0 is higher than Eiger BioPharmaceuticals Revenue of 12.142M.
Net Income: Poseida Therapeutics’s Net Income of -124974.0 is lower than Eiger BioPharmaceuticals Net Income of -33.917M.
Gross Profit: Poseida Therapeutics’s Gross Profit of 0.0 is lower than Eiger BioPharmaceuticals Gross Profit of 11.397M.
Ebitda: Poseida Therapeutics’s Ebitda of -128332.0 is lower than Eiger BioPharmaceuticals Ebitda of -37.412M.
P/E Ratio: Poseida Therapeutics’s P/E Ratio of -1.08 is lower than Eiger BioPharmaceuticals P/E Ratio of -4.26.
P/S Ratio: Poseida Therapeutics’s P/S Ratio of 110.29 is lower than Eiger BioPharmaceuticals P/S Ratio of 24.88.
P/B Ratio: Poseida Therapeutics’s P/B Ratio of 1.53 is lower than Eiger BioPharmaceuticals P/B Ratio of 2.48.
P/FCF Ratio: Poseida Therapeutics’s P/FCF Ratio of -1.26 is lower than Eiger BioPharmaceuticals P/FCF Ratio of -4.14.
ROE: Poseida Therapeutics’s ROE of -0.98 is higher than Eiger BioPharmaceuticals ROE of -0.61.
ROA: Poseida Therapeutics’s ROA of -0.59 is higher than Eiger BioPharmaceuticals ROA of -0.37.
Return On Capital Employed: Poseida Therapeutics’s Return On Capital Employed of -0.79 is higher than Eiger BioPharmaceuticals Return On Capital Employed of -0.71.
Gross Profit Margin: Poseida Therapeutics’s Gross Profit Margin of 0.0 is lower than Eiger BioPharmaceuticals Gross Profit Margin of 0.91.
Assets (Total): Poseida Therapeutics’s Assets (Total) of 269.309M is higher than Eiger BioPharmaceuticals Assets (Total) of 126.402M.
Debt (Total): Poseida Therapeutics’s Debt (Total) of 61.198M is lower than Eiger BioPharmaceuticals Debt (Total) of 84.6M.

Poseida Therapeutics vs Gamida Cell

Market Cap: Poseida Therapeutics’s Market Cap of 158642896 is higher than Gamida Cell Market Cap of 108572488.
Average Volume: Poseida Therapeutics’s Average Volume of 245156.0 is lower than Gamida Cell Average Volume of 726132.0.
Beta: Poseida Therapeutics’s Beta of 0.0 is lower than Gamida Cell Beta of 1.82.
Revenue: Poseida Therapeutics’s Revenue of 31238.0 is higher than Gamida Cell Revenue of 0.0.
Net Income: Poseida Therapeutics’s Net Income of -124974.0 is lower than Gamida Cell Net Income of 0.0.
Gross Profit: Poseida Therapeutics’s Gross Profit of 0.0 is lower than Gamida Cell Gross Profit of 0.0.
Ebitda: Poseida Therapeutics’s Ebitda of -128332.0 is lower than Gamida Cell Ebitda of 431000.0.
P/E Ratio: Poseida Therapeutics’s P/E Ratio of -1.08 is lower than Gamida Cell P/E Ratio of -1.76.
P/B Ratio: Poseida Therapeutics’s P/B Ratio of 1.53 is lower than Gamida Cell P/B Ratio of 4.31.
P/FCF Ratio: Poseida Therapeutics’s P/FCF Ratio of -1.26 is higher than Gamida Cell P/FCF Ratio of -1.07.
ROE: Poseida Therapeutics’s ROE of -0.98 is lower than Gamida Cell ROE of -1.21.
ROA: Poseida Therapeutics’s ROA of -0.59 is higher than Gamida Cell ROA of -0.49.
Return On Capital Employed: Poseida Therapeutics’s Return On Capital Employed of -0.79 is lower than Gamida Cell Return On Capital Employed of -0.84.
Assets (Total): Poseida Therapeutics’s Assets (Total) of 269.309M is higher than Gamida Cell Assets (Total) of 148.786M.
Debt (Total): Poseida Therapeutics’s Debt (Total) of 61.198M is lower than Gamida Cell Debt (Total) of 9.942M.
Shareholders Equity: Poseida Therapeutics’s Shareholders Equity of 156.211M is lower than Gamida Cell Shareholders Equity of 66.671M.

Poseida Therapeutics vs GeNeuro SA

Market Cap: Poseida Therapeutics’s Market Cap of 158642896 is higher than GeNeuro SA Market Cap of 53255284.
Average Volume: Poseida Therapeutics’s Average Volume of 245156.0 is higher than GeNeuro SA Average Volume of 2097.0.
Beta: Poseida Therapeutics’s Beta of 0.0 is lower than GeNeuro SA Beta of 0.56.
Revenue: Poseida Therapeutics’s Revenue of 31238.0 is higher than GeNeuro SA Revenue of 0.0.
Net Income: Poseida Therapeutics’s Net Income of -124974.0 is lower than GeNeuro SA Net Income of -6.818M.
Gross Profit: Poseida Therapeutics’s Gross Profit of 0.0 is lower than GeNeuro SA Gross Profit of 0.0.
Ebitda: Poseida Therapeutics’s Ebitda of -128332.0 is lower than GeNeuro SA Ebitda of -6.518M.
P/E Ratio: Poseida Therapeutics’s P/E Ratio of -1.08 is lower than GeNeuro SA P/E Ratio of -3.81.
P/S Ratio: Poseida Therapeutics’s P/S Ratio of 110.29 is lower than GeNeuro SA P/S Ratio of 18.73.
P/B Ratio: Poseida Therapeutics’s P/B Ratio of 1.53 is lower than GeNeuro SA P/B Ratio of 7.21.
P/FCF Ratio: Poseida Therapeutics’s P/FCF Ratio of -1.26 is lower than GeNeuro SA P/FCF Ratio of -2.95.
ROE: Poseida Therapeutics’s ROE of -0.98 is lower than GeNeuro SA ROE of -1.75.
ROA: Poseida Therapeutics’s ROA of -0.59 is lower than GeNeuro SA ROA of -0.73.
Return On Capital Employed: Poseida Therapeutics’s Return On Capital Employed of -0.79 is lower than GeNeuro SA Return On Capital Employed of -0.93.
Gross Profit Margin: Poseida Therapeutics’s Gross Profit Margin of 0.0 is lower than GeNeuro SA Gross Profit Margin of 0.0.
Assets (Total): Poseida Therapeutics’s Assets (Total) of 269.309M is higher than GeNeuro SA Assets (Total) of 12.54M.
Debt (Total): Poseida Therapeutics’s Debt (Total) of 61.198M is higher than GeNeuro SA Debt (Total) of 1.216M.

About Poseida Therapeutics

Poseida Therapeutics, Inc., a clinical biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. the company develops P-PSMA-101, a candidate product candidate for the chimeric antigen receptor T cell (CAR-T) that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). it also develops P-BCMA-ALLO1, which is in Phase I trial for patients with relapsed/refractory multiple myeloma, and P-MUC1C-ALLO1, which is in Phase I trial for treating a range of solid tumors, including breast, ovarian and other epithelial-derived cancers. in addition, the company is involved in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases, and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate for multiple myeloma. furthermore, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. in addition, the company is engaged in the development of P-OTC-101 and P-FVIII-101, which are clinically-based liver-directed gene therapies, and other allogeneic dual CAR candidates. it has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. the company was founded in 2014 and is headquartered in San Diego, California.

 

https://www.itsmypost.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here